UMB Bank n.a. Sells 202,585 Shares of Pfizer Inc. (NYSE:PFE)

UMB Bank n.a. decreased its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 37.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 336,143 shares of the biopharmaceutical company’s stock after selling 202,585 shares during the period. UMB Bank n.a.’s holdings in Pfizer were worth $9,678,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in Pfizer by 1.9% during the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after buying an additional 5,374,611 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley grew its holdings in shares of Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Pfizer in the fourth quarter worth $3,150,472,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. UBS Group cut their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Barclays decreased their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

View Our Latest Research Report on Pfizer

Pfizer Trading Down 0.6 %

Shares of PFE stock opened at $27.55 on Wednesday. The firm has a market capitalization of $156.00 billion, a P/E ratio of 76.53, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $27.43 and its 200 day simple moving average is $29.29.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.